MOLINFLAM

Molecular dissection of inflammatory pathways

Coordinatore	SEMMELWEIS EGYETEM    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Hungary [HU]
Totale costo	1˙200˙000 €
EC contributo	1˙200˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2007-StG
Funding Scheme	ERC-SG
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-10-01   -   2014-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	SEMMELWEIS EGYETEM  Organization address address: Ulloi ut 26 city: BUDAPEST postcode: 1085 contact info Titolo: Dr. Nome: Attila Cognome: Mocsai Email: send email Telefono: -7039 Fax: -7711	HU (BUDAPEST)	hostInstitution	0.00
2	SEMMELWEIS EGYETEM  Organization address address: Ulloi ut 26 city: BUDAPEST postcode: 1085 contact info Titolo: Ms. Nome: Irén Cognome: Baumgartnerné Holló Email: send email Telefono: +36 1 266 0119 Fax: +36 1 266 0119	HU (BUDAPEST)	hostInstitution	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Inflammatory diseases are highly prevalent, often chronic diseases that cause diminished quality of life and are connected with major causes of death in Western societies. Despite their societal impact, their pathomechanism is incompletely understood, hindering development of novel therapeutic strategies. In particular, little is known about the intracellular signal transduction processes involved in the tissue destruction phase of aggressive autoimmune diseases such as rheumatoid arthritis. The present proposal aims to clarify this issue using in vivo and in vitro studies on genetically manipulated mice. During the proposed studies, mice deficient in various signal transduction molecules such as Syk, PLCg2, Gab2 and p190 RhoGAPs will be used to test their contribution to inflammatory responses. In vitro studies will test the activation of major effector cells of inflammation (neutrophils, macrophages and osteoclasts) while in vivo studies will utilize mouse models such as autoantibody- and cytokine-induced inflammatory arthritis or autoantibody-induced glomerulonephritis. Further studies will be performed to test the contribution of the above signaling molecules to disease pathogenesis in a lineage-restricted manner, using the Cre-lox approach. Finally, wild type and mutant versions of the signaling molecules tested will be retrovirally re-expressed into the relevant knockout hematopoietic stem cells in vivo to allow structure-function studies during in vivo inflammation. Two novel transgenic strains and a knock-in (floxed) mutant will also be generated during the course of the project. Using state-of-the-art approaches and techniques, this project will provide information at unprecedented molecular detail on signal transduction mechanisms involved in inflammatory diseases, and is expected to point to possible future targets of novel anti-inflammatory therapies.'